Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Amazon Great Indian Festival 2020 - Electronics
Research

| More

Pharma - Sector Thematic - Cardiac: the heartbeat of domestic market - HDFC Securities Institutional Research Desk

Posted On: 2020-09-29 04:23:31


Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities

Cardiac is the largest therapy (Rs183bn in size) in the Indian pharma market (IPM), accounting for ~13% share in it and growing at 10% CAGR. We expect it to remain a dominant therapy for the next 10-15 years and gain 300-400bps share in the same period. Taking into cognizance the importance of this therapy, we deep dive into the Indian cardiac market to identify the potential winners in this space. Based on our analysis, Lupin, Glenmark, JB Chemicals, & Cipla are likely to gain market share among listed players, and Mankind & USV could gain market share among unlisted players.

A silent killer, cardiovascular disease accounts for one-third of global deaths: Cardiovascular disease (CVD) is the leading cause of mortality and accounts for ~18mn deaths every year, globally. With ageing demographics and changes in diet and lifestyle, this number is likely to increase in the coming years. The WHO estimates that by 2030, CVD would be responsible for more than 35% deaths in India (vs. 25% in 2016) with ischemic heart disease and stroke responsible for >80% of this burden.

Gains the leadership crown in India: Cardiac has displaced anti-infectives as the leading therapy in India (July 20) and has grown at 10% CAGR over the last four years, outperforming the IPM by 200bps. More importantly, the volume growth has been ~6%, which is double the industry average. While domestic firms dominate this market, the share of MNCs is restricted to less than 13%. Notwithstanding COVID disruption, the cardiac market grew at 10% YoY vs. 4% decline in IPM from Apr-Aug 20.

Hypertension drugs form 65% of the cardiac market: Broadly, the market is categorised based on treatments for hypertension, hyperlipidemia (high cholesterol), and thrombosis (blood clot). Hypertension (65%) - ARBs (sartans), calcium channel blockers (dipines) are growing faster than beta-blockers (prolols) and ace inhibitors (prils). Hyperlipidemia (19%) - Statins are by far the biggest and most important drug class to manage cholesterol. Thrombosis (14%) - Platelet aggregations inhibitors and clotting factor inhibitors are growing faster than the older drugs such as heparins.

Combination regimens, patented molecules are growing faster than market: Key distinct trends observed are as follows: (a) combination drugs for statins/sartans/beta blockers/calcium channel blockers are growing faster than monotherapy; (b) Diuretics (hypertension), clotting factor inhibitors (anti-thrombotic) are emerging as the fastest-growing drug class within respective categories; (c) patented/in-licensed molecules such as Entresto, Xarelto and Brilinta (recently went off patent) are growing significantly ahead of the market.

Lupin, Glenmark, JB chemicals, Cipla are potential winners: We have created a framework to rank companies based on key parameters that are critical to identifying potential outperformers in this space. The key determinants, among others, are (a) portfolio exposure to high-growth molecules; (b) covered market; (c) ability to build brands; (d) historical performance vs the IPM. Based on our analysis, Lupin, Glenmark, JB Chemicals, & Cipla are likely to gain market share among listed players, and Mankind & USV could gain market share among unlisted players. Top picks - Cipla, Lupin, and Aurobindo.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com

Amazon Great Indian Festival 2020 - Mobiles


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Havells India - Q2FY21 Result Update - ICICI Securities

Vardhman Textiles - Q2FY21 Company Update - ICICI Securities

Saregama India - Q2FY21 Company Update - ICICI Securities

Zensar Technologies - Q2FY21 Company Update - ICICI Securities

PI Industries - Q2FY21 Result Update - ICICI Securities

Derivatives Strategy - Positional Future - ICICI Securities

Grindwell Norton - Q2FY21 First Cut - ICICI Securities

Laurus Labs - Q2FY21 Result Update - ICICI Securities

Indian Oil Corporation - Q2FY21 First Cut - ICICI Securities

Mahindra Logistics - Q2FY21 First Cut - ICICI Securities

IndusInd Bank - Q2FY21 First Cut - ICICI Securities

ADD on Navin Fluorine International - EBITDA margin surprises positively! - HDFC Securities

Reiterate BUY on Larsen & Toubro - Marginal miss, bracing for recovery - HDFC Securities

US FDA tentative approval for Dapagliflozin - Zydus Cadila - Angel Broking

Maintain ADD on Radico Khaitan - Outperformance continues - HDFC Securities

Maintain REDUCE on V-Guard Industries - Muted performance continues - HDFC Securities

Cholamandalam Investment & Finance (CIFC) - Strong Set of numbers for Q2FY21 - Angel Broking

Maintain BUY on Maruti Suzuki - Festive cheer! - HDFC Securities

Can Fin Homes - Q2FY21 Result - Angel Broking

Maintain BUY on Hero Motocorp - Outperformance continues - HDFC Securities

Maintain ADD on Havells - Sharp margin recovery; Lloyd back on track - HDFC Securities

Maintain ADD on AU Small Finance Bank - Promising trends persist - HDFC Securities

Blue Star - Still not out of the woods - ICICI Securities

Larsen & Toubro - Treading cautiously - ICICI Securities

Blue Dart Express - Gross margins surprise - ICICI Securities

Gateway Distriparks - Multiple triggers at play - ICICI Securities

Piramal Enterprises - Consolidating wholesale mortgage; going LIVE with multi-asset retail lending - ICICI Securities

InterGlobe Aviation - Play on Covid recovery - ICICI Securities

Vodafone Idea Ltd - With AGR case behind, can VIL bounce back? - ICICI Securities

Power - Discom liquidity infusion scheme gains traction - ICICI Securities

Orient Cement - Higher prices, lower costs drive outperformance - ICICI Securities

Maruti Suzuki India - Quarter falls short of high expectations - ICICI Securities

PNB Housing Finance - Stress a cause of concern; business transformation a source of comfort - ICICI Securities

Gas sector - CGD draft regulations appear to favour new entrants - ICICI Securities

AU Small Finance Bank - Improving visibility on growth; progress on liability franchise gives comfort - ICICI Securities

Thyrocare Technologies - Pricing in the growth uptick - ICICI Securities

Strides Pharma Science - Steady quarter; growth to pick up - ICICI Securities

Hero MotoCorp - All eyes on the second half of festive season - ICICI Securities

Navin Fluorine International - Cashing-in new opportunities still far way - ICICI Securities

JM Financial - Measured growth, low risk tolerance to aid navigate the cycle well - ICICI Securities

Lemon Tree Hotels - Resilience amid turbulence - ICICI Securities

Larsen & Toubro Ltd - Q2FY21 Result Update - YES Securities

UTI AMC - Q2FY21 Result Update - YES Securities

VGuard Industries Ltd - Q2FY21 Result Update - YES Securities

Tata Coffee Ltd - Q2FY21 Result Update - YES Securities

AU Small Finance Bank Limited - Q2FY21 Result Update - YES Securities

Radico Khaitan Ltd - Q2FY21 Result Update - YES Securities

Can Fin Homes Limited - Q2FY21 Result Update - YES Securities

Reiterate ADD on Amara Raja Batteries - Pent-up demand leads to healthy 2Q - HDFC Securities

Maintain REDUCE on Titan - Reasonable print - HDFC Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019